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Abstract
Backgound: Thrombosis is regarded to be a key factor in the development of acute coronary
syndromes in patients with coronary artery disease (CAD). We hypothesize, that hemostatic and
rheological risk factors may be of major relevance for the incidence and the risk stratification of
these patients.
Methods: In 243 patients with coronary artery disease and stable angina pectoris parameters of
metabolism, hemostasis, blood rheology and endogenous fibrinolysis were assessed. Patients were
prospectively followed for 2 years in respect to elective revascularizations and acute coronary
syndromes.
Results: During follow-up 88 patients presented with cardiac events, 22 of those were admitted
to the hospital because of acute events, 5 Patients were excluded due to non- cardiac death.
Patients with clinical events were found to be more frequently diabetic and presented with a more
progressed coronary atherosclerosis. Even though patients with diabetes mellitus demonstrated a
comparable level of multivessel disease (71% vs. 70%) the rate of elective revascularization was
higher (41% vs. 28%, p < 0.05). The results were also unfavorable for the incidence of acute
cardiovascular events (18% vs. 8%, p < 0.01). In comparison to non-diabetic patients diabetics
demonstrated significantly elevated levels of fibrinogen (352 ± 76 vs. 312 ± 64 mg/dl, p < 0.01),
plasma viscosity (1.38 ± 0.23 vs. 1.31 ± 0.16 mPas, p < 0.01), red blood cell aggregation (13.2 ± 2.5
vs. 12.1 ± 3.1 E, p < 0.05) and plasmin-activator-inhibitor (6.11 ± 3.4 vs. 4.7 ± 2.7 U/l, p < 0.05).
Conclusion: Pathological alterations of fibrinogen, blood rheology and plasminogen-activator-
inhibtor as indicators of a procoagulant state are of major relevance for the short-term incidence
of cardiac events, especially in patients with diabetes mellitus type 2, and may be used to stratify
patients to specific therapies.
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Introduction
Apart from established, traditional cardiovascular risk fac-
tors like e.g. hypercholesterolemia, parameters of hemos-
tasis, endogenous fibrinolysis and platelet activity are
more and more recognized of being of importance in the
pathogenesis of atherosclerosis and acute coronary syn-
dromes especially in diabetic patients [1-9].
A recent study could show a diabetic specific coronary
morphology that is strongly related to hemostasis and
rheology [10]. Both parameters of endogenous fibrinoly-
sis and markers of platelet activity showed a relevant asso-
ciation on the extent of coronary sclerosis. The metabolic
changes with consecutive dysbalances of platelet activity,
hemostasis and endogenous fibrinolysis, and rheology
favor a prothrombotic milieu. These systemic changes
may result in an increased, thrombosis driven atheroscle-
rotic process [11], in part explaining the advanced coro-
nary plaque burden and in particular the more distal
pronounced distribution of coronary atherosclerosis in
patients with diabetes mellitus.
The potential role of these parameters for cardiovascular
events was shown in large epidemiological studies [12].
Coronary thrombosis is thought to play a major role for
the pathogenesis of acute coronary syndromes [13].
Therefore parameters indicating and predisposing arterial
thrombosis might be of major relevance for the higher
rate of cardiovascular events in patients with diabetes mel-
litus.
The present study characterizes the cardiovascular risk
profile of 243 patients evaluating the influence on the
occurrence of cardiovascular events. Besides of traditional
cardiovascular risk factors, parameters of hemostasis,
endogenous fibrinolysis and blood rheology were
assessed.
Methods
The study included a total of 264 consecutive patients
with CAD undergoing elective coronary angiography
either for suspected CAD or with suspected progression of
known CAD. Key exclusion criteria were unstable angina
pectoris, myocardial infarction within the last two
months, acute or chronic heart failure (NYHAIII or IV),
severe chronic and acute infection and malignant tumors.
With the beginning of the study the patients gave their
informed consent to additional blood sampling during
the routine investigation. The patients were informed in
detail about the aims of the study and that a follow up was
planned. After two years telephone interviews were carried
out. If patients could not be contacted by telephone or at
their addresses, their relatives or their general practition-
ers were contacted. As dependent variables for the follow-
up period of two years the occurrence of the following
events were examined: unstable angina pectoris, myocar-
dial infarction, cardiac death, non- cardiac death, elective
PTCA or ACB operation and acute cardiovascular revascu-
larization. In case of present unstable angina pectoris, sta-
ble but severe functional limitations of patients or an
inadequate medication, the interviewer contacted the gen-
eral practitioner for further information.
Definition of the cardiovascular risk profil
Hypercholesterolemia was presupposed with total choles-
terol above 220 mg/dl, with a positive history of hyperc-
holesterolemia and/or with lipid reducing therapies. The
same was assumed for hypertriglyceridemia above 200
mg/dl. Thus dyslipoproteinemia was diagnosed when
hypercholesterolemia or hypertriglyceridemia occured.
Hypertension was defined in patients with a resting blood
pressure above systolic 140 mmHg or diastolic 90 mmHg,
with a history of hypertension or with antihypertensive
medication. Nicotin consumption was assessed by his-
tory. Diabetes was defined by fasting plasma glucose con-
centration above 126 mg/dl or an antidiabetic therapy.
Recent studies suggest, that a high percentage of cardiac
patients present with newly diagnosed type 2 diabetes by
use of oral glucose tolerance tests (OGTT) [14-16]. OGTT
was not part of this protocol; therefore the true rate of dia-
betes may be underestimated.
Coronary Angiography
In all patients coronary angiograms with imaging of the
coronary arteries in different standardized projections
were carried out. The degree of coronary artery stenosis
was assessed by two experienced, independent examiners.
The severity of CAD was defined as coronary 1,2 or 3 ves-
sel disease corresponding to the number of affected main
vessels with hemodynamic relevant stenosis above 50%.
Extent of coronary sclerosis was determined by a special
grading system in accordance with an evaluation system
of the American Heart Association [17]. Based on these
findings the coronary artery system was divided into 15
segments. The segment with a higher degree of stenosis
got a higher score. The sum of these scores was divided by
the number of judged segments. The result presents the
extent of coronary atherosclerosis. To get information
about the distribution pattern of coronary sclerosis a prox-
imal score was calculated from the proximal segments and
a distal score was calculated from the distal segments of
the coronary arteries and of first degree branches.
Laboratory methods
Blood samples for the different studies were taken at the
day of cardiac catheterization between 7:00 and 8:00 am
according to a standardized protocol. Before venous punc-
ture was performed patients had spent a rest period in
lying position for 30 minutes. Venous puncture of anCardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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antecubital vene was done with a butterfly canula after a
maximum venous congestion time of 30 seconds and a
maximum congestion pressure of 40 mmHg. After decom-
pression the first 4 ml of blood were not used. Blood sam-
ples were sampled in vacutainer tubes. Samples were
frozen at a temperature of minus 80°C. For parameters of
hemostasis and endogenous fibrinolysis tubes with 0.129
M Na2 citrat were used. Determination of plasma viscosity
and red blood cell aggregation was performed from EDTA
tubes within 4 hours after sample taking. The samples
were analyzed immediately after preparation or from
deeply frozen plasma within three months after sample
taking.
Plasma fibrinogen levels were determined according to
method described by Clauss [18]. Plasmaviscosity was
determined by capillary tube viscosimeter of Rheomed,
Aachen (Germany). For determination of red blood cell
aggregation an erythrocyte aggregometer (Myrenne, Roet-
gen, Germany) according to the method of Schmid-
Schönbein [19] was used. Plasma tissue plasminogenacti-
vator antigen concentration was measured by enzymim-
munoassay. Determination of Plasminogenactivator
inhibitor activity was performed by chromogenic enzy-
massay.
Statistical methods
Statistical analyses were performed using SPSS software
(Statistical Package for Social Sciences for Windows; SPSS
12, Munich). The results were tested for normal distribu-
tion by Kolmogoroff-Smirnoff test. For normally distrib-
uted parameters group comparison was made by use of
paired and unpaired Student's t-test. Mann-Whitney U-
Test was used for non-normally distributed parameters.
The Pearson correlation coefficient or the Spearman's
rank correlations were used to describe the association
between the variables in the study. Chi square test was
used for comparison of non continuous data. Statistical
significance was defined as p < 0.05.
Results
Out of 264 originally selected patients a clinical course
after 2 years could be documented in 243 patients. Thus
the feed back rate was 91.3%. Patient characteristics are
given in table 1. Per definition in 150 patients there was
no cardiovascular event. Three patients died from non-
cardiac disease. Within the follow up period 88 patients
developed a cardiovascular event. 66 of them underwent
elective revascularization (figure 1). Of those 44 under-
went PTCA and 22 ACB bypass surgery. 22 patients suf-
fered from an acute cardiovascular event: 11 from an
Table 1: patient characteristics
clinical event without clinical event
n = 88 n = 150 p - value
age (in years) 58 ± 10 56 ± 11 n.s.
Male (%) 85 84 n.s.
risk profile
hypertension (%) 59 52 n.s.
diabetes mellitus 31 11 <0,001
hyperlipidemia (%) 78 78 n.s.
hypercholesterinemia (%) 69 70 n.s.
hypertriglyceridemia (%) 29 32 n.s.
history of smoking or smoking (%) 69 66 n.s.
positive family history (%) 44 42 n.s.
Anamnese
history of myokardial infarction (%) 44 51 n.s.
history of ACB operation (%) 10 5,4 n.s.
history of PTCA (%) 57 61 n.s.
Medication
nitrates (%) 87 80 n.s.
calcium channel blockers (%) 50 41 n.s.
betablockers (%) 41 46 n.s.
ace-inhibitors (%) 31 28 n.s.
thrombocytaggregationinhibitors (%) 73 78 n.s.
lipid lowering medication (%) 37 45 n.s.
insuline (%) 1,1 1,4 n.s.
oral andiabetic medication (%) 10 3,4 p < 0,05Cardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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unstable angina pectoris, 8 from an acute myocardial inf-
arction and 3 from a cardiac death. Related to the
observed group (n = 241) these figures correspond to an
elective rate of revascularization of 27,3% (PTCA, ACB)
and to an acute rate of events of 9,1%.
In regard to the characterization of patients those with
coronary ischemic event differed from those without an
event by a higher share of diabetic patients (see table 1).
Severity and extend of CAD
In assessing the severity and extend of coronary sclerosis it
became clear that there was a bigger share of coronary
multiple vessel disease (72%) in the group with clinical
event than in the group without clinical event (49%).
These results showed that the increased severity of CAD
also resulted in a higher extend of coronary sclerosis
which was reflected in proximal as well as distal distribu-
tion of coronary sclerosis (table 2)
Metabolic risk factors
There was no significant difference between the two
groups with regard to metabolic risk factors. Only blood
glucose discriminated which can be explained by the high
prevalence of diabetic patients with a clinical event in this
group (table 3).
Parameter of hemostasis and blood rheology
No difference could be found between the two groups
with regard to fibrinogen levels and rheological parame-
ters. Parameters of endogeneous fibrinolysis showed a sig-
nificant increase of tissue-plasminogen-activator in those
patients who suffered from a clinical event in the follow
up period (table 3).
Patients with diabetes mellitus
Cardiovascular events were significantly higher in the
group of diabetic patients with 64% compared to 31% in
the non- diabetic patients (figure 2). Even though patients
with DM demonstrated a comparable level of multivessel
disease in comparison to controls (71% vs. 70%) the rate
of elective revascularization was higher (41% vs. 28%, p <
0.05). The share of elective revascularization procedures
was higher in the group of nondiabetic patients, if only
the patients with an event were calculated (80% vs.
64.3%, p < 0.05). Three cardiac deaths in the non- dia-
betic group and no death in the diabetic patients did not
show significance. The results were also unfavorable for
the incidence of acute cardiovascular events (18.3% vs.
28.6%, p < 0.01).
Metabolic and hemostatic parameters
Due to a significant higher rate of cardiovascular events in
diabetic patients we further evaluated the metabolic and
hemostatic differences between patients with and without
diabetes mellitus (table 4 and figure 3). Diabetic patients
presented with lower HDL and higher LDL and triglycer-
ide- levels (see table 4). We did not assess long-term met-
abolic control with HbA1c. Although tissue-
plasminogenactivator was comparable between the 2
groups, plasminogen- activator- inhibitor was higher in
clinical events in 243 patients Figure 1
clinical events in 243 patients. Elective revascularizations 
include aorto-coronary bypass operation and angioplasty, 
acute events include unstable angina pectoris, acute myocar-
dial infarction and cardiac death.
Table 2: severity and extent of coronary atherosclerosis
clinical event without clinical event p-value
n = 88 n = 150
severity of coronary artery disease
1- vessel disease (%) 28 51
2 - vessel disease (%) 36 28
3 - vessel disease (%) 36 22 p < 0,01
extent of coronary atherosclerosis
total score 1,67 ± 0,71 1,31 ± 0,73 p < 0,001
proximal score 1,83 ± 0,74 1,49 ± 0,77 p < 0,001
distal score 1,43 ± 0,79 1,03 ± 0,70 p < 0,001Cardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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diabetic patients. Parameters of blood rheology were all
elevated in the group of patients with diabetes mellitus
(see figure 3).
Discussion
The presented results on the influence of rheological
parameters and factors of endogenous fibrinolysis on the
rate of clinical events showed that t-PA concentration is of
predictive importance within a follow up period of two
years. As the clinical rate of events in this study is essen-
tially determined by elective revascularisation the increase
of tPa in our study does not reflect so much the influence
on acute clinical events but points to the correlation
between tPa and severity and extend of coronary sclerosis,
respectively. The incidence of acute coronary events was
9.1% within the two year- period and thus roughly corre-
sponds to the estimated figure of 2-5% per year. Consid-
ering the share of patients with coronary multiple vessel
Table 3: parameters of metabolism, hemostasis endogenous fibrinolysis and blood rheology
clinical event without clinical event p-value
n = 88 n = 150
total cholesterol (mg/dl) 243 ± 49 238 ± 44 n.s.
hdl - cholesterol(mg/dl) 44 ± 11 45 ± 12 n.s.
ldl - cholesterol(mg/dl) 182 ± 49 173 ± 41 n.s.
triglycerides (mg/dl) 209 ± 143 185 ± 113 n.s.
lipoproteine (a) (mg/dl) 32 ± 39 34 ± 41 n.s.
uric acid (mg/dl) 5,8 ± 1,6 6,6 ± 1,7 n.s.
glucose (mg/dl) 108 ± 51 92 ± 35 <0,05
tissue -plasminogenactivator (μg/l) 9,3 ± 3,5 8,2 ± 3,0 <0,05
plasminogenaktivator-inhibitore (U/ml) 4,9 ± 2,5 4,9 ± 3,0 n.s.
fibrinogen (mg/dl) 330 ± 65 319 ± 70 n.s.
plasma viscosity (mPa × s-1) 1,3 ± 0,1 1,3 ± 0,2 n.s.
red blood cell aggregation M (E) 7,7 ± 2,4 7,5 ± 2,3 n.s.
red blood cell aggregation M1 (E) 12,4 ± 2,9 12,3 ± 3,0 n.s.
hematocrit (%) 43,6 ± 3,2 43,1 ± 3,1 n.s.
clinical events for patients with and without diabetes mellitus Figure 2
clinical events for patients with and without diabetes mellitus. Elective revascularizations include aorto-coronary 
bypass operation and angioplasty, acute events include unstable angina pectoris, acute myocardial infarction and cardiac death.Cardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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disease of 57% the rate of revascularization with 27.3% is
representative.
A disturbed endogenous fibrinolysis in diabetic patients
has been described in the past [4,9]. The proportion of
diabetics in the group with clinical events was relatively
high. The increase of t-PA can be judged by an elevation of
tPa - tPa inhibitor complexes and a consequently reduced
fibrinolysis due to an increase in tPa- inhibitor concentra-
tion [12]. In addition, a high extend of atherosclerosis in
coronary arteries and other vessel areas reflects a throm-
bogenic stimulus inducing a secondary, enhanced fibrino-
lytic activity. In a prior study from our group a parallel
increase of t-PA and PAP complexes was measured and
thus proved that an elevation of t-PA can reflect an
increased fibrinolytic activity [20]. Factors of blood rheol-
ogy had no predictive significance regarding the incidence
of cardiovascular events. This may be explained by the fact
that the described patients formed a group where coro-
nary artery disease was manifest while the majority of epi-
demiological investigations on the prospective
importance of fibrinogen were based on patients without
any evidence of coronary artery disease [21]. Moreover the
period of observation may have been to short and the
clinical rate of event to small to give a valid statement.
Based on different prospective studies especially fibrino-
gen is considered as a proven hemostatic factor for an
increased cardiovascular risk. A metaanalysis demon-
strated a 2.3 fold elevated cardiovascular risk for fibrino-
gen levels above 320 mg/dl [21]. In addition to an
impairment of hemostasis, blood rheology and platelet
reactivity and the consequent imbalance of the hemostatic
system (figure 4); fibrinogen may directly promote
atherogenesis [21].
Apart from patients with hyperfibrinogenemia there were
also patients with elevated t-PA and von Willebrand factor
with an increased rate of cardiovascular events affected
[12]. Other studies also found an elevated t-PA concentra-
tion as a risk factor of increased incidence of cardiovascu-
lar events. Data from the Physicians Health Study showed
a 2.8 fold increased risk between lowest and highest quin-
tile of t-PA concentration [22]. The importance of PAI is
underlined by a follow up study of men after primary
myocardial infarction. Those patients who showed ele-
vated PAI concentrations as a sign of reduced fibrinolysis
were at increased risk of reinfarction [23,24]. High con-
centrations of von Willebrand factor antigen are supposed
to be markers of endothelial lesions and present a proco-
agulative mechanism due to an inhanced platelet adhe-
sion [25].
The subset of patients with diabetes mellitus showed a
marked increase in the number of cardiovascular events,
favoring especially the number of acute events. This is in
correspondence to the literature, which reports also a
higher incidence of acute cardiovascular events like acute
myocardial infarction and cardiac death [26] and also a
higher incidence of revascularization procedures [27]. The
potential role of insulin in atherogenesis has been dis-
cussed for 25 years [28]. Results of various prospective
studies indicated that elevated plasma insulin levels cause
and enhance atherosclerosis [29-31]. Diverse diseases
associated with hyperinsulinemia like the metaboliv syn-
drome, hypertension, adipositas and hypertriglyceri-
demia show an early and extended manifestation of
atherosclerosis [32-37]. Several studies proved that ele-
vated insulin levels are accompanied by reduced endog-
enous fibrinolysis [1-3,5,7]. On the one hand
hyperinsulinemia is associated with a decreased t-PA con-
Table 4: parameters of metabolism, hemostasis, endogenous fibrinolysis and blood rheology for patients with and without diabetes 
mellitus
diabetes mellitus non-diabetic patients p-value
n = 44 n = 194
total cholesterol (mg/dl) 254 ± 69 239 ± 43 n.s.
hdl - cholesterol(mg/dl) 42 ± 13 45 ± 12 <0,05
ldl - cholesterol(mg/dl) 188 ± 55 173 ± 43 <0,05
triglycerides (mg/dl) 257 ± 204 183 ± 103 <0,05
lipoproteine (a) (mg/dl) 22 ± 33 36 ± 42 <0,05
glucose (mg/dl) 157 ± 67 88 ± 12 <0,0001
tissue -plasminogenactivator (μg/l) 8,9 ± 3,7 8,4 ± 3,0 n.s.
plasminogenaktivator-inhibitore (U/ml) 6,1 ± 5,2 4,8 ± 2,7 <0,05
fibrinogen (mg/dl) 351 ± 76 312 ± 64 <0,01
plasma viscosity (mPa × s-1) 1,38 ± 0,23 1,31 ± 0,16 <0,01
red blood cell aggregation M (E) 8,7 ± 2,1 7,3 ± 2,0 <0,05
red blood cell aggregation M1 (E) 13,2 ± 2,5 12,1 ± 3,1 <0,05Cardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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Rheology in diabetic patients Figure 3
Rheology in diabetic patients. Between Patients with and without type 2 diabetes mellitus significant differences were 
found for fibrinogen (A), red blood cell (RBC) aggregation (B), plasma viscosity (C) and Plasminogenactivator-Inhibitor (PAI) 
(D).Cardiovascular Diabetology 2009, 8:48 http://www.cardiab.com/content/8/1/48
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centration [5], on the other hand it causes an increase of
PAI activity [1-3,7].
Rheological properties in general are a major factor deter-
mining microcirculatory function and blood flow. Plasma
viscosity and red blood cell aggregation are decisive rheo-
logical parameters of microcirculation. Erythrocyte aggre-
gation is described to be closely linked to fibrinogen and
alpha2- macroglobulin [38]. A fibrinogen mediated
increase of both is not relevant in non- obstructed epicar-
dial arteries under normal circumstances. Impaired blood
rheology can restrict coronary blood flow and cause criti-
cally myocardial oxygen and nutrition supply in the area
of poststenotic microcirculation of successive multiple
linked stenoses and collateralized occlusions with heavily
impaired vasomotion [39]. Diabetic patients present with
impaired hemorheology, as also shown in this study.
Patients with diabetes mellitus and stroke have more
often an impaired hemorheology as non-diabetic patients
[40]. Secondary microcirculatory complications are also
associated with higher erythrocyte aggregation and viscos-
ity [41].
Hemorheological disorders are strongly related to meta-
bolic control (HbA1c), lipid parameters and hyperin-
sulinemia [42,43]. Red blood cell deformability is
mediated by nitric oxide, as well as red blood cell aggrega-
tion [44]. Nitric oxide is well known to be markedly
reduced in patients with type 2 diabetes mellitus and well
accepted as a marker of endothelial function. Thus, the
rheological impairment of diabetic patients is related to
endothelial dysfunction and a possible cause of both
micro- and macrovascular complications.
Conclusion and Future Perspective
In summary, pathological alterations of fibrinogen, blood
rheology and plasminogen-activator-inhibtor as indica-
tors of a procoagulant state (figure 4) are of relevance for
the short-term incidence of cardiac events, especially in
patients with diabetes mellitus type 2. Diabetes predis-
poses to those multiple alterations, which in turn can
have multiple effects on atherosclerosis, vascular mor-
phology and cardiovascular events. The possible link
between endothelial dysfunction, red blood cell function
and pathological rheology and hemostasis may, in part,
connect micro- and macrovascular complications with
diabetes mellitus. More research is needed to elucidate
these potential mechanisms and possibly develop a tai-
lored therapy for these diabetes specific mechanisms of
atherothrombotic disease.
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